Zoetis Inc. (ZTS) Stake Increased by Retirement Systems of Alabama
Retirement Systems of Alabama increased its position in Zoetis Inc. (NYSE:ZTS) by 7.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 250,380 shares of the company’s stock after buying an additional 17,650 shares during the period. Retirement Systems of Alabama owned 0.05% of Zoetis worth $13,022,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently added to or reduced their stakes in the company. NEXT Financial Group Inc boosted its stake in shares of Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock valued at $101,000 after buying an additional 186 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA boosted its stake in shares of Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock valued at $116,000 after buying an additional 1,300 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock valued at $121,000 after buying an additional 476 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock valued at $139,000 after buying an additional 124 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its stake in shares of Zoetis by 94.6% in the third quarter. Penserra Capital Management LLC now owns 2,720 shares of the company’s stock valued at $140,000 after buying an additional 1,322 shares during the last quarter. Institutional investors own 92.41% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) traded up 0.46% on Wednesday, reaching $50.68. 1,862,887 shares of the company’s stock were exchanged. Zoetis Inc. has a 1-year low of $38.26 and a 1-year high of $53.14. The company has a 50 day moving average price of $50.03 and a 200-day moving average price of $49.67. The company has a market capitalization of $25.03 billion, a PE ratio of 36.54 and a beta of 1.05.
Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.46 by $0.06. The business earned $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. Zoetis’s revenue was up 2.2% on a year-over-year basis. During the same quarter last year, the company earned $0.50 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post $1.94 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be given a dividend of $0.095 per share. The ex-dividend date of this dividend is Tuesday, November 1st. This represents a $0.38 annualized dividend and a dividend yield of 0.75%. Zoetis’s dividend payout ratio (DPR) is presently 27.54%.
TRADEMARK VIOLATION WARNING: “Zoetis Inc. (ZTS) Stake Increased by Retirement Systems of Alabama” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of United States & international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/11/30/zoetis-inc-zts-stake-increased-by-retirement-systems-of-alabama.html.
Several analysts have commented on the stock. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Monday. Citigroup Inc. boosted their target price on shares of Zoetis from $50.00 to $53.00 and gave the company a “neutral” rating in a research note on Thursday, August 4th. Barclays PLC boosted their target price on shares of Zoetis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Thursday, August 4th. Jefferies Group reiterated a “buy” rating and issued a $60.00 target price on shares of Zoetis in a research note on Tuesday, August 23rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $58.00 target price on shares of Zoetis in a research note on Wednesday, October 12th. Two analysts have rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $55.92.
In related news, insider Andrew Fenton sold 13,870 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $51.25, for a total transaction of $710,837.50. Following the completion of the transaction, the insider now owns 17,719 shares in the company, valued at approximately $908,098.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael B. Mccallister bought 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The shares were bought at an average price of $51.34 per share, with a total value of $102,680.00. The disclosure for this purchase can be found here. Corporate insiders own 0.05% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.